GSK's asth­ma drug Nu­cala gets speedy re­view for rare blood dis­or­der

Glax­o­SmithK­line’s asth­ma drug Nu­cala may not be on the same tier as ri­val Re­gen­eron’s Dupix­ent, but it has scored a speedy re­view for use in a rare blood dis­or­der.

First ap­proved in 2015 for se­vere eosinophilic asth­ma, Nu­cala (known chem­i­cal­ly as mepolizum­ab) tar­gets IL-5. The British drug­mak­er on Wednes­day dis­closed that the mon­o­clon­al an­ti­body se­cured pri­or­i­ty re­view from the FDA for pa­tients with hy­per­e­osinophilic syn­drome (HES) — a group of life-threat­en­ing in­flam­ma­to­ry dis­or­ders char­ac­ter­ized by a per­sis­tent over­pro­duc­tion of a type of white blood cell called eosinophils.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.